Arialys Therapeutics…announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to ART5803 for the treatment of pediatric patients with anti-NMDA receptor encephalitis (ANRE).

ART5803 - Arialys Therap

Sep 25, 2025